CRISPR technology offers innovative solutions for pandemic preparedness, enhancing diagnostics, antiviral therapies, and ...
Tulane University researchers have developed a CRISPR-based test that diagnoses Pneumocystis jirovecii pneumonia (PJP) - a ...
Antibiotic resistance is a global concern that threatens our ability to prevent and treat bacterial infections in humans and ...
Try Now>> See the top stocks recommended by analysts >> Read More on CRSP: CRISPR Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
She covers the COVID-19 pandemic, new drug developments in cancer and Alzheimer's disease, mental health, HIV, CRISPR, and advances in gene therapy, among other issues in health and science.
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the shares. While Casgevy is making progress based on 2024 ...
using adeno-associated virus with transposon-based delivery of the CRISPR guide RNAs. This study presents an updated split Cas12a system that enables amplification-free detection of the RNA with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback